FdaApplication
NDA 219947
Identifiers
- fda_app_no: NDA219947
Properties
| Property | Value |
|---|---|
| applicant_name | ARROWHEAD PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2025-11-18 |
Revenue by product
REDEMPLO
| Period | Revenue |
|---|---|
| Q2 2026 | $75.3M† |
| Q1 2026 | $73.7M† |
| Q4 2025 | $264.0M† |
| Q3 2025 | $256.5M† |
| Q2 2025 | $27.8M† |
| Q1 2025 | $542.7M† |
| Q4 2024 | $2.5M† |
| Q3 2024 | $0.0M† |
| Q2 2024 | $0.0M† |
| Q1 2024 | $0.0M† |
| Q4 2023 | $3.6M† |
| Q3 2023 | $16.1M† |
| Q2 2023 | $15.8M† |
| Q1 2023 | $146.3M† |
| Q4 2022 | $62.5M† |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one. A figure marked † is the company's one reported revenue line rather than a product breakdown.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| REDEMPLO | PLOZASIRAN SODIUM | EQ 25MG BASE/0.5ML (EQ 25MG BASE/0.5ML) | SOLUTION;SUBCUTANEOUS |
1 product